The USP <85> Bacterial Endotoxins Test (BET) is the United States Pharmacopeia chapter governing the determination of bacterial endotoxins in parenteral products, raw materials, pharmaceutical water and medical devices. It is one of the most critical tests in the QC laboratory: an out-of-limit result can block the release of a sterile batch, and a poorly designed test — wrong endotoxin limit, dilution beyond the MVD, inadequate controls — is among the most frequent findings in FDA and EMA inspections. In this practical guide we look at how the LAL test works, how to choose between methods, how to calculate USP <85> endotoxin limits and the Maximum Valid Dilution, and what changes with the arrival of recombinant reagents (USP <86>).
What USP <85> covers and why it is harmonized
Bacterial endotoxins are lipopolysaccharides (LPS) from the outer membrane of Gram-negative bacteria: they are heat-stable, survive standard sterilization and, if injected, can cause fever, septic shock and intravascular coagulation. This is why every injectable product must demonstrate an endotoxin content below a defined limit.
The test relies on the amebocyte lysate of Limulus polyphemus (LAL, Limulus Amebocyte Lysate), which clots in the presence of endotoxins by activating an enzymatic cascade. USP <85> is harmonized through the Pharmacopeial Discussion Group (PDG) with Ph. Eur. 2.6.14 and the Japanese Pharmacopoeia: the harmonized text has been official since December 1, 2012, which allows — with the appropriate verifications — a single protocol to serve the US, EU and Japanese markets. The FDA has also published the guidance "Pyrogen and Endotoxins Testing: Questions and Answers", which addresses the most common operational questions on sampling, pooling and retesting.
The scope is broad: finished parenteral products, APIs and raw materials intended for injectables, Water for Injection (WFI), primary packaging components in contact with the product, and depyrogenated glassware. For each category, the quality system must define the sampling point, the frequency and the applicable limit, with a documented rationale.
The three LAL test methods
USP <85> describes three techniques, all compendial and all acceptable provided the laboratory demonstrates their suitability for the specific product:
- Gel-clot: the referee method in case of dispute. Qualitative or semi-quantitative, based on the formation of a visible gel; it requires confirmation of the labeled lysate sensitivity (λ) on each new reagent lot.
- Turbidimetric (kinetic or endpoint): photometrically measures the increase in turbidity; quantitative, well suited to high sample volumes.
- Chromogenic (kinetic or endpoint): measures the release of a chromophore (pNA) from a synthetic substrate; it is the most widely used in modern QC laboratories for its sensitivity and dynamic range.
Photometric methods require a standard curve of at least three concentrations with a correlation coefficient |r| ≥ 0.980, and every analytical run must include the positive product control (PPC) with a recovery between 50% and 200%: this demonstrates that the matrix neither inhibits nor enhances the reaction.
If you work in QC or QA and want to receive practical cases, pharmacopoeia updates and hands-on tools like this guide every week, subscribe to The Pragmatic GMP, GuideGxP's free weekly newsletter: endotoxins, OOS, audits and much more, without unnecessary theory.
Endotoxin limits and MVD: the calculations to keep under control
The endotoxin limit for a parenteral product is calculated with the formula EL = K/M, where K is the threshold pyrogenic dose per kg of body weight and M is the maximum dose of product per kg per hour. The K values are set by the pharmacopoeias and the FDA guidance:
| Parameter | Value | Operational notes |
|---|---|---|
| K — parenteral route (non-intrathecal) | 5 EU/kg/h | Applies to most injectables |
| K — intrathecal route | 0.2 EU/kg/h | A limit 25 times stricter: watch out for dual-route products |
| M — maximum dose | mg or mL/kg/h | Use the maximum labeled dose; standard body weight of 70 kg for adults |
| MVD | (EL × concentration)/λ | Maximum dilution beyond which the test is not valid |
The Maximum Valid Dilution is where the most expensive mistakes concentrate: diluting beyond the MVD to "make an interference disappear" invalidates the result and, if documented in a batch record, becomes a data integrity finding on top of a microbiology one. The correct strategy is to characterize the interference during method validation (inhibition/enhancement) and set a working dilution within the MVD, justified in the protocol.
USP <86> and recombinant reagents: what changes
Since May 2025, the new chapter USP <86> "Bacterial Endotoxins Test Using Recombinant Reagents", published for early adoption in November 2024, has been official. The chapter covers the recombinant reagents rFC (recombinant Factor C) and rCR (recombinant Cascade Reagent), which eliminate the dependence on horseshoe crab blood. Key points to know:
- USP <86> does not replace USP <85>: it is an additional chapter, and LAL remains fully compendial.
- Anyone adopting recombinant reagents must demonstrate the suitability of the method for their own product (sensitivity, specificity, reproducibility), following the chapter's own instructions.
- In Europe, the parallel reference is Ph. Eur. 2.6.32 for the rFC test: for multi-market products it is worth mapping the requirements of both pharmacopoeias before converting the method.
Typical audit findings
In inspections and internal audits on the BET, the same findings recur: endotoxin limit calculated on the average dose instead of the maximum dose; MVD not recalculated after a change in concentration or λ; PPC outside the 50-200% range accepted without investigation; lysate lots used without verification of the labeled sensitivity; WFI water trends not analyzed (continuous water monitoring is the first indicator of system drift); glassware depyrogenation not revalidated. Each of these points should have an SOP, an owner and a defined verification frequency.
GuideGxP recommendation
Treat the BET as a full analytical method, not as a routine test: suitability validation for every product and every matrix, EL and MVD calculations signed and version-controlled, standard curve acceptance criteria written into the SOP, OOS handling according to the laboratory procedure, and periodic trending of water and product results. In an audit, the question will not be "do you run the LAL test?" but "show me that your limit and your dilution are justified": that is where the finding is won or lost.
To manage compendial requirements across USP, Ph. Eur., JP and BP in a defensible way — including the endotoxin chapters and alternative methods — the operational guide Pharmacopoeias in GMP – Operational Guide to USP, Ph. Eur., JP and BP is available with a ready-to-use toolkit for the QC laboratory.
